• Castle Biosciences highlighted a newly published patient-and-caregiver study on atopic dermatitis treatment selection, reinforcing demand for its AdvanceAD-Tx test.
• Results were already presented via publication in Dermatology and Therapy, not slated for a future medical meeting.
• Survey responses pointed to frequent therapy changes tied to unmet treatment goals, underscoring inconsistent real-world control on current options.
• Most respondents signaled strong interest in molecular testing to help choose a systemic therapy, supporting adoption potential for AdvanceAD-Tx.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609241630PR_NEWS_USPR_____DA56487) on September 24, 2026, and is solely responsible for the information contained therein.